Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISC-hpNSC neural stem cell therapy in Parkinson's disease
NCT02452723Phase 1Completed
- Start
- Jul 2016
- Primary completion
- Jun 2025
- Modality
- Neural Stem Cells, Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ISC-hpNSC in Parkinson's disease (PD). Primary endpoint: Treatment-Emergent Adverse Events at 12 months. Started Jul 2016; status: completed.
02
Drugs
ISC-hpNSC
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02452723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02452723.